Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.56 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.52 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15564614 | 1.00 | TRPM8 (0.56) | TRPM8TRPA1EPHX1KCNA5ALDH1A1 | |
| SCHEMBL7103829 | 1.00 | TRPM8 (0.56) | TRPM8TRPA1EPHX1KCNA5ALDH1A1 | |
| SCHEMBL30604482 | 0.77 | TRPM8 (0.62) | TRPM8TRPA1EPHX1KCNA5ALDH1A1 | |
| SCHEMBL10612768 | 0.76 | TRPM8 (0.56) | TRPM8TRPA1EPHX1KCNA5ALDH1A1 | |
| SCHEMBL767051 | 0.76 | — | — | |
| SCHEMBL21349959 | 0.75 | TRPM8 (0.60) | TRPM8TRPA1EPHX1KCNA5ALDH1A1 | |
| SCHEMBL26770470 | 0.75 | TRPM8 (0.60) | TRPM8TRPA1EPHX1KCNA5ALDH1A1 | |
| SCHEMBL9080881 | 0.75 | TRPM8 (0.60) | TRPM8TRPA1EPHX1KCNA5ALDH1A1 | |
| SCHEMBL19719730 | 0.75 | TRPM8 (0.60) | TRPM8TRPA1EPHX1KCNA5ALDH1A1 | |
| SCHEMBL2761364 | 0.75 | TRPM8 (0.60) | TRPM8TRPA1EPHX1KCNA5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108025001-A | Gamma secretase modulators for the treatment of immune system dysfunction | 安可初克公司 | 2018-05-11 | — | — | CN | claimed |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | CEPHALON, INC. (US) | 2011-06-16 | — | — | US | claimed |
| US-7915236-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-03-29 | — | — | US | claimed |
| EP-1660507-B9 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-03-24 | — | — | EP | claimed |
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2009-11-26 | — | — | US | claimed |
| EP-1660507-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2009-08-05 | — | — | EP | claimed |
| EP-1948601-A1 | FAB I INHIBITOR AND PROCESS FOR PREPARING SAME | Crystalgenomics, Inc. (KR) | 2008-07-30 | — | — | EP | claimed |
| US-20070135465-A1 | Fab I Inhibitor and Process for Preparing Same | CRYSTALGENOMICS, INC. (KR) | 2007-06-14 | — | — | US | claimed |
| WO-2007043835-A1 | FAB I INHIBITOR AND PROCESS FOR PREPARING SAME | CRYSTALGENOMICS, INC. (KR) | 2007-04-19 | — | — | WO | claimed |
| EP-1622610-B1 | 1-(2H-PYRAZOL-3-YL)-3-{4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | AVENTIS PHARMA INC (US) | 2006-12-20 | — | — | EP | claimed |
| EP-1660507-A2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2006-05-31 | — | — | EP | claimed |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | US | claimed |
| WO-2005021558-A2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2005-03-10 | — | — | WO | claimed |
| WO-1998017646-A1 | 1-(4-PIPERDINYL)-PIPERIDINYLENE AS AGGREGATION INHIBITOR | DR. KARL THOMAE GMBH (DE) | 1998-04-30 | — | — | WO | claimed |
| EP-0023454-B1 | PROCESS FOR THE PREPARATION OF 6,6-DIMETHYL-4-HYDROXY-3-OXABICYCLO(3.1.0)HEXAN-2-ONE AND ITS ETHERS OF ALL POSSIBLE STEREOISOMERIC FORMS | ROUSSEL-UCLAF (FR) | 1983-06-22 | — | — | EP | claimed |
| EP-4076730-A1 | MULTI-FUNCTIONAL HYBRID MATERIAL BASED ON SEPIOLITE FOR ENVIRONMENTAL RECOVERY AND BIO-REMEDIATION | Consiglio Nazionale Delle Ricerche (IT) | 2022-10-26 | — | — | EP | disclosed |
| WO-2021124097-A1 | MULTI-FUNCTIONAL HYBRID MATERIAL BASED ON SEPIOLITE FOR ENVIRONMENTAL RECOVERY AND BIO-REMEDIATION | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 2021-06-24 | — | — | WO | disclosed |
| EP-0023454-B1 | PROCESS FOR THE PREPARATION OF 6,6-DIMETHYL-4-HYDROXY-3-OXABICYCLO(3.1.0)HEXAN-2-ONE AND ITS ETHERS OF ALL POSSIBLE STEREOISOMERIC FORMS | ROUSSEL-UCLAF (FR) | 1983-06-22 | — | — | EP | disclosed |
| EP-0024241-A1 | Sulphonated compounds comprising a lactone ring and the preparation of cyclopropane derivatives therefrom | ROUSSEL-UCLAF (FR) | 1981-02-25 | — | — | EP | disclosed |
| US-3936479-A | 2-BENZAMIDO-BENZOPHENONES, UV STABILIZERS, PLASTICS | SANDOZ LTD., (SANDOZ AG) (CH) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | PSMB11, PSMB5, PSMB6 | TRPM8 4814/4885TRPA1 4791/4885EPHX1 2993/4885 |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | TRPM8 4814/4885TRPA1 4791/4885EPHX1 2993/4885 |
| US-20070135465-A1 | Fab I Inhibitor and Process for Preparing Same | TFPI, TFPI2, FCGRT | TRPM8 4603/4885TRPA1 4830/4885EPHX1 4222/4885 |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | PSMB11, PSMB5, PSMB6 | TRPM8 4814/4885TRPA1 4791/4885EPHX1 2993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.